MedTrace Logo

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

NCT03472313 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-10-22

No results posted yet for this study

Summary

The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[18F]MNI-958

Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • Jennifer Madonia, PA-C · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-04-20
Completion
2018-04-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472313 on ClinicalTrials.gov